A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis

National Institute of Allergy and Infectious Diseases (NIAID)

Overview

To determine the safety and effectiveness of intravenous ganciclovir (also known as DHPG) in the treatment of sight-threatening cytomegalovirus (CMV) retinitis in patients with AIDS. CMV retinitis is a severe vision-threatening viral infection of the retina of the eye. It occurs in patients whose immune function has been impaired and is the most common cause of blindness in patients with AIDS. Ganciclovir (GCV) improved the signs and symptoms of CMV retinitis in approximately 80 percent of the patients treated for 2 weeks, but almost all of the patients treated with GCV had a relapse after treatment was stopped. Thus, it is important to determine if GCV can be safely given over a long period of time (maintenance therapy) and if it is effective in preventing a relapse of CMV retinitis.

CMV retinitis is a severe vision-threatening viral infection of the retina of the eye. It occurs in patients whose immune function has been impaired and is the most common cause of blindness in patients with AIDS. Ganciclovir (GCV) improved the signs and symptoms of CMV retinitis in approximately 80 percent of the patients treated for 2 weeks, but almost all of the patients treated with GCV had a relapse after treatment was stopped. Thus, it is important to determine if GCV can be safely given over a long period of time (maintenance therapy) and if it is effective in preventing a relapse of CMV retinitis. Patients are given GCV intravenously for 14 days. Then the patient receives the same dose, but only once a day, for as long as therapy is tolerated. If the retinitis worsens during the maintenance phase, the patient may again be given GCV for 14 days. Long-term treatment with GCV usually requires the surgical placement of a catheter in a large central vein in the chest or groin that is left in place indefinitely. If this is required, the procedure will be explained to the patient.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Masking

NONE

Conditions

Cytomegalovirus Retinitis HIV Infections

Interventions

GanciclovirDRUG

Eligibility

Sex: ALLMin age: 3 Months

Medical Language ↔ Plain English

Inclusion Criteria Concurrent Medication: Allowed: * Aerosolized pentamidine prophylaxis for Pneumocystis carinii pneumonia. * Topical ophthalmics. * Topical acyclovir. Concurrent Treatment: Allowed: * Hemodialysis for patients with renal impairment. Patients must have: * Diagnosis of AIDS and immediately sight-threatening cytomegalovirus retinitis. Prior Medication: Allowed: * Zidovudine. * Prior therapy for retinitis. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Non-immediately sight-threatening cytomegalovirus retinitis. Concurrent Medication: Excluded: * Systemic investigational agents such as antimetabolites, alkylating agents, nucleoside analogs, acyclovir sodium (Zovirax). * Interferon. * Cytokines. * Foscarnet (non-nucleoside pyrophosphate analog). * Ganciclovir may be withheld for up to 21 days for an acute course with an investigational or toxic therapy or oral / IV acyclovir. Patients with the following are excluded: * Non-immediately sight-threatening cytomegalovirus retinitis.

Locations (1)

Natl Inst of Allergy & Infect Dis / Cln Ctr

Bethesda, Maryland, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.